RecruitingPHASE1, PHASE2NCT04938817
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Studying Autosomal dominant multiple pterygium syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- coformulation pembrolizumab/quavonlimab(biological)
- Enrollment
- 110 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2029
Study locations (30)
- Banner MD Anderson Cancer Center ( Site 0152), Gilbert, Arizona, United States
- Northside Hospital-Northside Hospital Oncology Network ( Site 0156), Atlanta, Georgia, United States
- Parkview Research Center at Parkview Regional Medical Center ( Site 0180), Fort Wayne, Indiana, United States
- Baptist Health Lexington-Research ( Site 0158), Lexington, Kentucky, United States
- University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0157), Lexington, Kentucky, United States
- MFSMC-HJWCI-Oncology Research ( Site 0178), Baltimore, Maryland, United States
- Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0172), Omaha, Nebraska, United States
- Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0179), Omaha, Nebraska, United States
- Cleveland Clinic-Taussig Cancer Center ( Site 0166), Cleveland, Ohio, United States
- UPMC Hillman Cancer Center ( Site 0177), Pittsburgh, Pennsylvania, United States
- St Francis Cancer Center-Research Office ( Site 0167), Greenville, South Carolina, United States
- Virginia Cancer Institute ( Site 0169), Richmond, Virginia, United States
- Westmead Hospital-Department of Medical Oncology ( Site 4004), Westmead, New South Wales, Australia
- The Prince Charles Hospital-Oncology Clinical Trials ( Site 4003), Brisbane, Queensland, Australia
- Monash Health-Oncology Research ( Site 4005), Clayton, Victoria, Australia
- +15 more locations on ClinicalTrials.gov
Collaborators
Daiichi Sankyo
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04938817 on ClinicalTrials.govOther trials for Autosomal dominant multiple pterygium syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06941012Validation of α-synuclein Modifications in Parkinson's dIsoRder EvolutionCasa di Cura IGEA
- RECRUITINGNCT06949670Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTianjin Medical University
- RECRUITINGPHASE3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT05281003Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Fudan University
- ACTIVE NOT RECRUITINGPHASE1NCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Merck Sharp & Dohme LLC
- RECRUITINGNCT07533799The Swedish BioFINDER Sleep StudySkane University Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCAstraZeneca
- RECRUITINGNCT04724941Prodromal Alpha-Synuclein Screening in Parkinson's Disease StudyUniversity Hospital Schleswig-Holstein
See all trials for Autosomal dominant multiple pterygium syndrome →